Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Finished Goods for 3 consecutive years, with $9.3 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 338.05% to $9.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Dec 2025, up 338.05% year-over-year, with the annual reading at $9.3 million for FY2025, 338.05% up from the prior year.
  • Finished Goods hit $9.3 million in Q4 2025 for Krystal Biotech, up from $7.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $9.3 million in Q4 2025 to a low of $161000.0 in Q1 2024.
  • Historically, Finished Goods has averaged $3.5 million across 3 years, with a median of $2.1 million in 2024.
  • Biggest YoY gain for Finished Goods was 3563.35% in 2025; the steepest drop was 4.03% in 2025.
  • Year by year, Finished Goods stood at $627000.0 in 2023, then surged by 239.07% to $2.1 million in 2024, then soared by 338.05% to $9.3 million in 2025.
  • Business Quant data shows Finished Goods for KRYS at $9.3 million in Q4 2025, $7.3 million in Q3 2025, and $1.7 million in Q2 2025.